A Phase 3 interventional study of Ruxolitinib in Primary Myelofibrosis (MF), sponsored by Novartis Pharmaceuticals. Completed at 29 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-07-11.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies testing ruxolitinib in Primary Myelofibrosis — 8 open to participants now, 15 under way, 1 of them phase 3. ruxolitinib · Primary Myelofibrosis.
Among the 50 studies testing ruxolitinib in Primary Myelofibrosis, this one is the 19th largest by enrollment, is one of 3 that started in 2014, is one of 6 in phase 3, and was the 20th registered.
627 studies on the registry are indexed under Primary Myelofibrosis; 125 are open to participants now.
Browse Primary Myelofibrosis studies →8 of the 50 studies testing ruxolitinib in Primary Myelofibrosis are open now, in 1 country. Recruiting first, the newest first:
University of Utah · Sites in United States
Ages 18+
Fred Hutchinson Cancer Center · Sites in United States
Ages 18–75
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18–75
By country, each count listing its studies:
ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 101 Primary Myelofibrosis studies recruiting now, 83 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 27 · Phase 3 6 · Phase 4 4
First in 2007; this study’s year is marked. 3 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 51 is above the median of 43 across 491 interventional studies indexed under Primary Myelofibrosis.
Median enrollment 45 across the 50 interventional studies. Of the 32 that completed or were terminated, 23 (72%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 50 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,721 studies on the registry; 222 are open to participants now.
Of its 586 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
24 studies in Primary Myelofibrosis by Novartis: 1 open now, 4 under way, 2 of them phase 3. Of 18 finished, 12 (67%) have results posted.
Among the 24 studies in Primary Myelofibrosis by Novartis, this one is the 11th largest by enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2014, is one of 7 in phase 3, and was the 12th registered.
Novartis’s Primary Myelofibrosis studies by the year they started, since 2001.
6 of the studies testing ruxolitinib in Primary Myelofibrosis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04041050AbbVieA Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm | 2026-12-31 |
| NCT05714072Memorial Sloan Kettering Cancer CenterA Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis | 2027-01 |
| NCT06345495M.D. Anderson Cancer CenterHigh Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly | 2027-01-01 |
| NCT05371964Geron CorporationA Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis | 2027-02 |
| NCT03069326Memorial Sloan Kettering Cancer CenterA Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis | 2027-02 |
Add all 6 to your calendar (.ics) → With an account.
Among the 50 studies testing ruxolitinib in Primary Myelofibrosis, from their registry updates:
Among Novartis’s 24 in Primary Myelofibrosis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an open-label, multicenter clinical study in order to collect and examine data concerning the safety and efficacy of ruxolitinib in patients with Primary Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF, Post-Essential Thrombocythemia (ET) MF.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The following values for bone marrow function prior to treatment:
Exclusion Criteria:
Hepatic or renal impairment as indicated by the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ruxolitinib was administered orally twice daily at the starting dose of 5 mg, 15 mg or 20 mg bid based on Baseline platelet counts. The dosage was subsequently adjusted for safety and efficacy so that each patient was titrated to their most appropriate dose.
Drug: Ruxolitinib
Number of Participants With Adverse Events as a Measure of Safety and Tolerability
Time frame: 24 weeks
Charge in Spleen Size From Baseline at Specified Week
Number of patients with spleen length reduced by ≥ 50% at specified week
Time frame: Baseline, 24 weeks
Charge in Spleen Size From Baseline up to the Specified Week
Number of patients with spleen length reduced by ≥ 50% up to specified week
Time frame: Baseline, 24 weeks
Summary of Total Symptom Score as Measured by Seven-day Modified Myelofibrosis Symptom Assessment Form (MFSAF) v2.0 by Time
The modified MFSAF v2.0 diary captures a patient's symptom severity on a scale of 0 (absent) to 10 (worst imaginable),with a maximal summary score of 60
Time frame: 24 weeks
Summary of Summary of EORTC QLQ-C30 Responses by Time
The QLQ-C30 version 1.0 (QLQ-C30) incorporates five functional scales (physical, role, cognitive, emotional, and social), three symptom scales (fatigue, pain, and nausea and vomiting), a global health status / QoL scale, and a number of single items assessing additional symptoms commonly reported by cancer patients (dyspnoea, loss of appetite, insomnia, constipation and diarrhea) and perceived financial impact of the disease.All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Thus a high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems.
Time frame: 24 weeks
| Milestone | Ruxolitinib |
|---|---|
| Started | 51 |
| Completed | 44 |
| Not completed | 7 |
| Withdrew: Disease progression | 1 |
| Withdrew: Adverse event | 5 |
| Withdrew: Lost to follow-up | 1 |
| Participants | Ruxolitinib |
|---|---|
| AEs, regardless of study treatment relationship | 50 |
| AEs suspected to be related to study treatment | 46 |
| SAEs, regardless of study treatment relationship | 12 |
| SAEs suspected to be related to study treatment | 5 |
| AEs of CTC grade 3/4, regardless study treatment | 36 |
| AEs of CTC grade 3/4 suspected related treatment | 33 |
| AEs leading to the study treatment discontinuation | 5 |
| AEs requiring reduction or interruption treatment | 38 |
| AEs requiring concomitant medication | 33 |
Number of patients with spleen length reduced by ≥ 50% at specified week
| particiapants | Ruxolitinib |
|---|---|
| Week 2 | 12 |
| Week 4 | 14 |
| Week 8 | 14 |
| Week 12 | 11 |
| Week 16 | 14 |
| Week 20 | 13 |
| Week 24 | 15 |
Number of patients with spleen length reduced by ≥ 50% up to specified week
| particiapants | Ruxolitinib |
|---|---|
| Week 4 | 18 (13.1 to 38.2) |
| Week 8 | 22 (16.2 to 42.5) |
| Week 12 | 23 (16.2 to 42.5) |
| Week 16 | 26 |
| Week 20 | 26 |
| Week 24 | 26 |
The modified MFSAF v2.0 diary captures a patient's symptom severity on a scale of 0 (absent) to 10 (worst imaginable),with a maximal summary score of 60
| score on a scale | Ruxolitinib |
|---|---|
| Night Sweats baseline (n=51) | 2.9 ± 3.07 |
| Night Sweats week 24 (n=43) | 0.6 ± 1.35 |
| Itching baseline (n=51) | 1.8 ± 2.39 |
| Itching week 24 (n=43 | 0.6 ± 1.25 |
| Abdominal Discomfort baseline( n=51) | 4.4 ± 3.18 |
| Abdominal Discomfort week 24(n=43) | 1.4 ± 1.84 |
| Pain under ribs on left Baseline (=51) | 2.2 ± 2.72 |
| Pain under ribs on left week 24 (=43) | 0.7 ± 1.26 |
| Feeling of fullness Baseline (n=51) | 3.2 ± 2.91 |
| Feeling of fullness week 24 (n=43) | 1.3 ± 1.8 |
| Bone/muscle pain Baseline (n=51) | 2.3 ± 2.83 |
| Bone/muscle pain week 24 (n=43) | 1.0 ± 1.83 |
| Degree of inactivity Baseline (n=51) | 2.3 ± 2.84 |
| Degree of inactivity week 24 (n=43) | 1.0 ± 1.66 |
| Total symptom score baseline (n=51) | 16.8 ± 12.30 |
| Total symptom score week 24 (n=43) | 5.7 ± 6.48 |
The QLQ-C30 version 1.0 (QLQ-C30) incorporates five functional scales (physical, role, cognitive, emotional, and social), three symptom scales (fatigue, pain, and nausea and vomiting), a global health status / QoL scale, and a number of single items assessing additional symptoms commonly reported by cancer patients (dyspnoea, loss of appetite, insomnia, constipation and diarrhea) and perceived financial impact of the disease.All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Thus a high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems.
| units on a scale | Ruxolitinib |
|---|---|
| Physical Functioning baseline | 79.35 ± 17.951 |
| Physical Functioning 24(n=43) | 86.67 ± 17.959 |
| Role Functioning Baseline(n=51) | 77.78 ± 23.254 |
| Role Functioning Week 24(n=43) | 83.72 ± 19.068 |
| Emotional Functioning Baseline(n=51) | 85.46 ± 17.705 |
| Emotional Functioning Week 24(n=43) | 92.05 ± 13.357 |
| Cognitive Functioning Baseline(n=51) | 78.43 ± 20.356 |
| Cognitive Functioning week 24 (n=43) | 79.84 ± 17.653 |
| Social Functioning Baseline (n=51) | 85.62 ± 19.154 |
| Social Functioning week 24(n=43) | 87.60 ± 17.852 |
| Global Health Status/QOL Baseline (n=51) | 55.72 ± 22.882 |
| Global Health Status/QOL week 24 (n=43) | 66.47 ± 22.456 |
| Fatigue Baseline(n=51) | 40.31 ± 23.787 |
| Fatigue week 24 (n=43) | 28.68 ± 23.412 |
| Nausea and Vomiting baseline (n=51) | 4.90 ± 13.862 |
| Nausea and Vomiting week 24 (n=43) | 0.39 ± 2.542 |
| Pain Baseline | 21.57 ± 21.678 |
| Pain week 24 (n=43) | 10.08 ± 15.911 |
| Dyspnoea baseline (n=51) | 22.88 ± 25.377 |
| Dyspnoea Week 24 (n=43) | 25.58 ± 23.946 |
| Insomnia baseline (n=51) | 23.53 ± 29.283 |
| Insomnia Week 24 (n=43) | 15.50 ± 23.400 |
| Appetite Lose baseline (n=51) | 21.57 ± 27.787 |
| Appetite Lose Week 24 (n=43) | 9.30 ± 16.786 |
| Constipation baseline (n=51) | 8.50 ± 20.916 |
| Constipation Week 24 (n=43) | 8.53 ± 16.416 |
| Diarrhoea baseline (n=51) | 18.30 ± 24.325 |
| Diarrhoea Week 24 (n=43) | 12.40 ± 23.029 |
| Financial Difficulties baseline (n=51) | 15.69 ± 25.257 |
| Financial Difficulties Week 24 (n=43) | 20.93 ± 30.012 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ruxolitinib | — | 12/51 (23.5%) | 49/51 (96.1%) |
| Event | Ruxolitinib |
|---|---|
| AnaemiaBlood and lymphatic system disorders | 1/51 |
| Disseminated intravascular coagulationBlood and lymphatic system disorders | 1/51 |
| Cardiac failure congestiveCardiac disorders | 1/51 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 1/51 |
| Oesophageal varices haemorrhageGastrointestinal disorders | 1/51 |
| Multi-organ failureGeneral disorders | 1/51 |
| Drug-induced liver injuryHepatobiliary disorders | 1/51 |
| EmpyemaInfections and infestations | 1/51 |
| SepsisInfections and infestations | 1/51 |
| Urinary tract infectionInfections and infestations | 1/51 |
| Event | Ruxolitinib |
|---|---|
| AnaemiaBlood and lymphatic system disorders | 32/51 |
| ThrombocytopeniaBlood and lymphatic system disorders | 15/51 |
| Platelet count decreasedInvestigations | 12/51 |
| ConstipationGastrointestinal disorders | 7/51 |
| Hepatic function abnormalHepatobiliary disorders | 6/51 |
| NasopharyngitisInfections and infestations | 6/51 |
| PyrexiaGeneral disorders | 5/51 |
| Electrocardiogram QT prolongedInvestigations | 5/51 |
| Abdominal painGastrointestinal disorders | 4/51 |
| DiarrhoeaGastrointestinal disorders | 4/51 |
| Age, Continuous(years) | Ruxolitinib |
|---|---|
| Mean | 65.7 ± 8.8 |
| Sex: Female, Male(Participants) | Ruxolitinib |
|---|---|
| Female | 24 |
| Male | 27 |
The record gives a start of Apr 2014, a primary completion of Mar 2015 and a completion of Apr 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2016, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ruxolitinib